Interviews
“There Are Good Grounds for Being Very Cynical About Western Elites”
Ahead of his visit to the Stigler Center on October 25, Edward Luce, Washington columnist for the Financial Times and author of The Retreat of...
“In Just About Every Generation, Many People Thought the American Republic was on the Verge of Collapse”
The second installment of our two-part interview with Harvard Business School professor David Moss about his recent book Democracy: A Case Study. "One of the reasons...
How to Defeat Populist Plutocrats? “Build a Counter-Narrative”
Beppe Severgnini, one of the most influential journalists in Italy, talks to ProMarket about what the U.S. can learn from Italy on how to defeat...
Can “Productive Tensions” Save American Democracy Again?
This is the first installment of a two-part interview we had with David Moss about his recently published book Democracy: A Case Study, which contains...
“A Slow, Creeping Consolidation of Power by Big Money Over Think Tanks in the United States”
Following his ouster from New America, antitrust scholar Barry Lynn talks to ProMarket about academic capture and the power of digital platforms like Google.
Over the...
Bo Rothstein Explains Why He Resigned From Oxford Over Donor's Link to Donald Trump
In an interview with ProMarket, Swedish political scientist Bo Rothstein explains why he decided to resign from the Blavatnik School of Government after learning...
Eliot Spitzer: The Democratic Party Has Become the Party of the Status Quo
Former New York governor Eliot Spitzer talks about antitrust, digital platforms, economic concentration, and regulatory capture. Part 2 of 2.
In the first part of...
Eliot Spitzer: The U.S. Never Had the Will and the Ability to Hold the Most Powerful to Account
In a special interview with ProMarket, former New York governor Eliot Spitzer talks about financial regulation, regulatory capture, and antitrust. Part 1 of 2.
Clear rules and...
"The Pharmaceutical Industry Has a Large Amount of Control Over the Field of Oncology"
In the second part of our two-part interview with Daniel Goldstein, MD, an oncologist who studies the influence of business interests on healthcare, we talk...
When Medical Experiments Serve the Business Needs of Pharmaceutical Firms Instead of Science
The first part of a two-part interview with Daniel Goldstein, MD, an oncologist who also studies the influence of business interests on healthcare—from treating patients...
